Compare GSK plc (GSK) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lumen Technologies Inc — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while Lumen Technologies Inc trades at $6.35 (market cap $6.56B). The key difference: GSK plc is far larger — about 15.4× Lumen Technologies Inc's market cap, and GSK plc pays a 3.49% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| GSK | LUMN | |
|---|---|---|
Market Cap | $101.34B | $6.56B |
Sector | Health | Media |
52-Week High | $61.18 | $11.83 |
52-Week Low | $36.20 | $3.70 |
Enterprise Value | $121.95B | $18.19B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
LUMN trades at $6.37, showing no change recently, with a bearish technical signal and mixed earnings history. The company reported a net loss of $1.74B in 2025, though revenue remains substantial at $12.40B. Recent developments include the acquisition of Alkira to enhance AI networking capabilities and cost-cutting initiatives targeting $1B in savings by 2027. Analyst consensus is cautious, with a hold-heavy rating distribution and a $8.25 price target.
The outlook is challenging due to persistent losses and high debt, but strategic acquisitions and efficiency efforts offer potential upside. Risks include execution hurdles and competitive pressures in telecom. Investors should weigh the low P/S ratio against profitability concerns before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
